weekly_roundup
BioTechSign Daily Catalyst Roundup - November 20, 2026
Top BioTechSign catalyst names today: EYPT, MLTX, GRFS, ARGX, NUVB, BBIO. FDA, clinical trial, grade-change, dilution, and sentiment signals.
BiotechSign AnalysisNovember 20, 2026
Daily Biotech Catalyst Digest: November 20, 2026
EYPT leads the current BioTechSign screen at 83.5/100 with a grade of A. The daily view combines FDA timing, clinical activity, publications, dilution risk, short interest, institutional/fund flow, and market-sentiment convergence into one research queue.
Top Catalyst Scores
| Ticker | Company | Score | Grade | Strongest Inputs |
|---|---|---|---|---|
| EYPT | EyePoint, Inc. | 83.5 | A | clinical activity 100%, short interest 50%, dilution risk 47% |
| MLTX | MoonLake Immunotherapeutics | 80.5 | A | clinical activity 100%, short interest 50%, publication signal 35% |
| GRFS | Grifols SA | 74.8 | B | publication signal 100%, clinical activity 100%, dilution risk 19% |
| ARGX | argenx SE | 74.0 | B | publication signal 100%, clinical activity 100%, dilution risk 15% |
| NUVB | Nuvation Bio | 73.6 | B | clinical activity 88%, PDUFA timing 75%, short interest 70% |
| BBIO | BridgeBio Pharma | 73.2 | B | PDUFA timing 100%, publication signal 100%, clinical activity 100% |
Recent Grade-Change Queue
- INSM (Insmed Incorporated) currently grades C with a 54.8/100 catalyst score. Main inputs: publication signal 100%, clinical activity 58%, dilution risk 50%.
- FDMT (4D Molecular Therapeutics, Inc.) currently grades C with a 52.4/100 catalyst score. Main inputs: publication signal 90%, short interest 70%, clinical activity 54%.
- NKTR (Nektar Therapeutics) currently grades C with a 52.7/100 catalyst score. Main inputs: publication signal 100%, short interest 90%, clinical activity 75%.
- MLYS (Mineralys Therapeutics, Inc.) currently grades C with a 53.6/100 catalyst score. Main inputs: PDUFA timing 75%, dilution risk 51%, short interest 50%.
- DNLI (Denali Therapeutics) currently grades D with a 39.8/100 catalyst score. Main inputs: publication signal 100%, clinical activity 62%, short interest 50%.
- RARE (Ultragenyx Pharmaceutical) currently grades F with a 26.6/100 catalyst score. Main inputs: publication signal 100%, short interest 70%, dilution risk 37%.
- EYPT (EyePoint, Inc.) currently grades A with a 83.5/100 catalyst score. Main inputs: clinical activity 100%, short interest 50%, dilution risk 47%.
- PTCT (PTC Therapeutics) currently grades D with a 44.2/100 catalyst score. Main inputs: clinical activity 75%, short interest 50%, dilution risk 29%.
What To Watch
Names with high clinical-trial and publication inputs deserve a pipeline read-through. Names with elevated dilution or short-interest inputs deserve tighter risk review before any catalyst trade. The purpose of this feed is to surface candidates for research, not to make buy or sell recommendations.